Preclinical development

F-star Therapeutics Announces Collaboration with MSD to Evaluate FS120 in Combination with KEYTRUDA

Wednesday, August 4, 2021 - 1:00pm

Under the terms of the agreement, MSD will supply KEYTRUDA for a combination arm that will be included in theadaptive Phase 1 clinical protocol of FS120, sponsored by F-star,thatwas initiatedin December of 2020.

Key Points: 
  • Under the terms of the agreement, MSD will supply KEYTRUDA for a combination arm that will be included in theadaptive Phase 1 clinical protocol of FS120, sponsored by F-star,thatwas initiatedin December of 2020.
  • FS120 is currently being exploredas a monotherapy in dose escalation (NCT04648202) , including the evaluation of pharmacokinetics and pharmacodynamics in patients with advanced cancer.
  • FS120 will also be evaluated in combination withKEYTRUDA,with the potential for early demonstration of clinical activity in specifictumorsubtypes.
  • In preclinical studies, FS120 has demonstrated strong additive effects in combination with PD-1 monoclonal antibodies.

OnKure Expands Executive Team with the Addition of Chief Scientific Officer and Chief Development Officer

Tuesday, August 3, 2021 - 5:00pm

He joined Arvinas as the Chief Scientific Officer, helping the new company focus on a novel technology, validating and further advancing this technology, and building a growing preclinical pipeline, enabling Arvinas to go public.

Key Points: 
  • He joined Arvinas as the Chief Scientific Officer, helping the new company focus on a novel technology, validating and further advancing this technology, and building a growing preclinical pipeline, enabling Arvinas to go public.
  • I am thrilled to be joining forces with such an experienced team of drug discovery and development scientists, said Dr. Winkler.
  • Dr. Walker has a proven track record in cancer drug discovery and development, including contributions to the discovery and development of three FDA-approved medicines.
  • OnKure has reconstituted a management team that has previously worked together to create breakthrough precision cancer medicines, said Tony Piscopio, Ph.D., Co-Founder, President and Chief Executive Officer of OnKure.

BenchSci Extends Impact on Drug Discovery With Addition of AI-Assisted Animal Model Selection

Wednesday, July 28, 2021 - 1:00pm

BenchSci enables scientists to make more informed and precise animal model selections by providing evidence of successful utilization in experiments similar to their own.

Key Points: 
  • BenchSci enables scientists to make more informed and precise animal model selections by providing evidence of successful utilization in experiments similar to their own.
  • "We're proud to be introducing animal models to the BenchSci platform as we continue to focus on helping scientists accelerate preclinical research," says Casandra Mangroo, BenchSci's SVP of Product and Science.
  • Scientists will have the information they need to select the most appropriate animal model to advance their experiments."
  • BenchSci's animal model database includes:
    The addition of animal models to the platform is one more way that BenchSci is becoming a complete resource for all aspects of decision-making in experimental design.

Goldfinch Bio Announces Upcoming Presentations at the 13th International Podocyte Conference

Tuesday, July 27, 2021 - 1:00pm

The oral presentation will detail how Goldfinch Bios novel transplanted human organoid approach for preclinical pharmacokinetic (PK) and PD studies improves upon the limited predictive power and translatability of standard animal model studies to the human condition.

Key Points: 
  • The oral presentation will detail how Goldfinch Bios novel transplanted human organoid approach for preclinical pharmacokinetic (PK) and PD studies improves upon the limited predictive power and translatability of standard animal model studies to the human condition.
  • Also at the conference, Goldfinch Bio will present an e-poster presentation detailing its approach to developing novel medicines for podocytopathies, including GFB-887.
  • We have a robust pipeline of novel, precision medicine product candidates targeting kidney diseases with significant unmet need, including two clinical-stage assets.
  • In 2020, Goldfinch Bio was named one of Fierce Biotechs Fierce 15 companies.

Oligomerix to Present at Alzheimer's Association International Conference

Monday, July 26, 2021 - 1:30pm

Oligomerix plans to complete preclinical testing of OLX-07010 by year end and begin Phase 1 clinical trials by 2Q22.

Key Points: 
  • Oligomerix plans to complete preclinical testing of OLX-07010 by year end and begin Phase 1 clinical trials by 2Q22.
  • Oligomerix is headquartered at the Westchester Park Center in White Plains, New York and has lab facilities at the Ullmann Research Center for Health Sciences within the Albert Einstein College of Medicine.
  • Oligomerix is seeking strategic partners to support the acceleration and advancement of these important programs.
  • For more information about Oligomerix, please visit our new website at https://oligomerix.com/ .

Collaborative Drug Discovery (CDD) Launches BioHarmony

Monday, July 26, 2021 - 11:57am

SAN FRANCISCO, July 26, 2021 /PRNewswire/ -- Collaborative Drug Discovery, Inc. (CDD), provider of the web-based drug discovery informatics platform CDD Vault, announces the launch of a new data offering named BioHarmony. BioHarmony provides semantically curated live feeds of drug data from diverse sources.

Key Points: 
  • New Data Offering Provides LIVE Feeds about Drugs from Diverse Sources (Pre-clinical, Clinical & Post-Clinical)
    SAN FRANCISCO, July 26, 2021 /PRNewswire/ -- Collaborative Drug Discovery, Inc. (CDD), provider of the web-based drug discovery informatics platform CDD Vault, announces the launch of a new data offering named BioHarmony .
  • BioHarmony provides semantically curated live feeds of drug data from diverse sources.
  • Requests for new feeds are available "On-Demand" for any individual drug or sets of drugs for comparison studies.
  • CDD also offers the BioHarmony Drug Data Store, providing semantic data on preclinical, clinical, and post-approval developments.

Collaborative Drug Discovery (CDD) Launches BioHarmony

Monday, July 26, 2021 - 11:57am

SAN FRANCISCO, July 26, 2021 /PRNewswire/ -- Collaborative Drug Discovery, Inc. (CDD), provider of the web-based drug discovery informatics platform CDD Vault, announces the launch of a new data offering named BioHarmony. BioHarmony provides semantically curated live feeds of drug data from diverse sources.

Key Points: 
  • New Data Offering Provides LIVE Feeds about Drugs from Diverse Sources (Pre-clinical, Clinical & Post-Clinical)
    SAN FRANCISCO, July 26, 2021 /PRNewswire/ -- Collaborative Drug Discovery, Inc. (CDD), provider of the web-based drug discovery informatics platform CDD Vault, announces the launch of a new data offering named BioHarmony .
  • BioHarmony provides semantically curated live feeds of drug data from diverse sources.
  • Requests for new feeds are available "On-Demand" for any individual drug or sets of drugs for comparison studies.
  • CDD also offers the BioHarmony Drug Data Store, providing semantic data on preclinical, clinical, and post-approval developments.

Alzamend Neuro Receives Positive Results for AL002 in a GLP Toxicology Study Using a Transgenic Mouse Model of Alzheimer’s Disease

Friday, July 23, 2021 - 11:30am

Alzamend Neuro, Inc. (Nasdaq: ALZN) (Alzamend), a preclinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, today announced that it has received positive toxicology results for AL002 in a good laboratory practices (GLP) toxicology study using a transgenic mouse model of Alzheimers disease.

Key Points: 
  • Alzamend Neuro, Inc. (Nasdaq: ALZN) (Alzamend), a preclinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, today announced that it has received positive toxicology results for AL002 in a good laboratory practices (GLP) toxicology study using a transgenic mouse model of Alzheimers disease.
  • The positive GLP toxicology results represent a key milestone for Alzamend as we continue to advance our proprietary pipeline.
  • We believe AL002 could potentially reverse the effects of Alzheimers disease.
  • A five-dose GLP study with AL002-sensitized cells was completed using a transgenic (or genetically modified) mouse model of Alzheimers disease to investigate the tolerability of AL002.

The Worldwide Clinical Trial Industry is Expected to Reach a Value of $57+ Billion by 2026 - ResearchAndMarkets.com

Thursday, July 22, 2021 - 5:36pm

Research centers and numerous organizations enhance clinical trials' productivity and effectiveness by advancing and managing clinical trials globally.

Key Points: 
  • Research centers and numerous organizations enhance clinical trials' productivity and effectiveness by advancing and managing clinical trials globally.
  • After preclinical development, the investigational new drug passes through clinical phases I, II, III, and IV during the clinical trial.
  • It expected that the Global Clinical Trials Market will expand, registering a CAGR of 14.13% during the forecast period, 2020-2026.
  • North America is a conventional clinical trial region, and because of the legal, regulatory considerations, the clinical trial market shifted to developing nations.

Bioasis Technologies Inc. Announces Stock Option Grants, Jeffrey Sprouse Appointed Preclinical Program Manager

Tuesday, July 20, 2021 - 9:05pm

NEW HAVEN, Conn., July 20, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it has granted stock options to acquire a total of 1,367,606 common shares effective June 30, 2020 at a price of $0.38 per share to directors and officers of the Company and an investor relations consultant. All of the options expire five years from the date of the grant and are governed by the terms of the company’s stock option plan. The options are being issued as part of annual remuneration in lieu of cash compensation as the company prioritizes investment in partnership enhancing R&D.

Key Points: 
  • All of the options expire five years from the date of the grant and are governed by the terms of the companys stock option plan.
  • The company also announced the appointment of Dr. Jeffrey Sprouse PhD as Preclinical Program Manager.
  • Dr. Sprouse brings over 20 years of drug discovery experience to his role at Bioasis.
  • Since 2010, Dr. Sprouse has served as an industry consultant, managing all aspects of preclinical programs.